Prothena Corporation Announces New Compensation Agreements for Key Executives, Including Enhanced Severance Benefits

Reuters
Jul 31
Prothena Corporation Announces New Compensation Agreements for Key Executives, Including Enhanced Severance Benefits

Prothena Corporation plc has announced new employment agreements for key executives at its subsidiary, Prothena Biosciences Inc. Effective July 30, 2025, Tran B. Nguyen, Chief Strategy Officer and CFO; Brandon S. Smith, COO; and Wagner M. Zago, Ph.D., Chief Scientific Officer, will receive annual base salaries of $603,792, $544,201, and $518,000 respectively. Each will be eligible for a discretionary annual cash bonus, with target percentages set at 50% for Nguyen and Smith, and 40% for Zago. In cases of termination without cause or resignation with good reason, the executives will receive severance benefits including 100% of their base salary and target bonus, plus up to 12 months of health coverage. These benefits increase to 150% of base salary and target bonus, and up to 18 months of health coverage, if termination occurs in connection with a change in control. The agreements also include provisions for accelerated vesting of equity awards.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-169367), on July 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10